Drug-eluting particles for interventional pharmacology

Eleni Liapi; Kwang-Hun Lee; Christos C Georgiades; Kelvin Hong; Jean-Francois H Geschwind

doi:10.1053/j.tvir.2008.03.003

Drug-eluting particles for interventional pharmacology

Tech Vasc Interv Radiol. 2007 Dec;10(4):261-9. doi: 10.1053/j.tvir.2008.03.003.

Authors

Eleni Liapi¹, Kwang-Hun Lee, Christos C Georgiades, Kelvin Hong, Jean-Francois H Geschwind

Affiliation

¹ The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Hospital, Baltimore, MD, USA.

PMID: 18572139
DOI: 10.1053/j.tvir.2008.03.003

Abstract

Chemoembolization with drug-eluting particles has been recently introduced in the field of interventional oncology. In this review, we will describe the pharmacokinetic properties and efficacy of all commercially available or under investigation drug-eluting particles and discuss the potentials and future of this new form of transcatheter arterial therapy for liver cancer.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / administration & dosage*
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Carcinoma, Hepatocellular / secondary
Carcinoma, Hepatocellular / therapy
Chemoembolization, Therapeutic* / adverse effects
Colorectal Neoplasms / secondary
Colorectal Neoplasms / therapy
Doxorubicin / administration & dosage
Drug Carriers
Humans
Irinotecan
Liver Neoplasms / therapy*
Lung Neoplasms / secondary
Lung Neoplasms / therapy
Microspheres

Substances

Antineoplastic Agents
Drug Carriers
Irinotecan
Doxorubicin
Camptothecin